WO1998010762A3 - Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride - Google Patents
Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride Download PDFInfo
- Publication number
- WO1998010762A3 WO1998010762A3 PCT/GB1997/002418 GB9702418W WO9810762A3 WO 1998010762 A3 WO1998010762 A3 WO 1998010762A3 GB 9702418 W GB9702418 W GB 9702418W WO 9810762 A3 WO9810762 A3 WO 9810762A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alpha
- controlled release
- methoxyimino
- dosage form
- release dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9711734A BR9711734A (en) | 1996-09-12 | 1997-09-08 | Controlled-release dosage form of ¬r- (z) alfa-alpha- (metÄxiimino) -alpha- (1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile monochlorochloride |
PL97332074A PL332074A1 (en) | 1996-09-12 | 1997-09-08 | Dosable administration form of controllable release of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo-[2,2,2]oct-3-yl) acetonitrile monohydrochloride |
NZ334268A NZ334268A (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride |
EP97939064A EP0929301A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo 2.2.2]oct-3-yl)acetonitrile monohydrochloride |
CZ99832A CZ83299A3 (en) | 1996-09-12 | 1997-09-08 | Dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyklo[2,2,2]okt-3-yl)acetonitrile monohydrochloride with controlled release |
IL12878197A IL128781A0 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride |
AU41288/97A AU724086B2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride |
JP10513352A JP2001500150A (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of [R- (Z)]-α- (methoxyimino) -α- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile monohydrochloride |
CA002265661A CA2265661A1 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl)acetonitrile monohydrochloride |
HU9904401A HUP9904401A3 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride |
NO991194A NO991194D0 (en) | 1996-09-12 | 1999-03-11 | Controlled-release dosage form of [R- (Z) - <alfa> - (methoxyimino) - <alfa> - (azabicyclo [2,2,2] oct-3-yl) acetonitrile monohydrochloride |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
GB9619074.9 | 1996-09-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09254621 A-371-Of-International | 1999-03-11 | ||
US09/759,576 Continuation US20010003588A1 (en) | 1996-09-12 | 2001-01-12 | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998010762A2 WO1998010762A2 (en) | 1998-03-19 |
WO1998010762A3 true WO1998010762A3 (en) | 1998-06-04 |
Family
ID=10799833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0929301A2 (en) |
JP (1) | JP2001500150A (en) |
KR (1) | KR20000036039A (en) |
CN (2) | CN1235544A (en) |
AR (1) | AR008176A1 (en) |
AU (1) | AU724086B2 (en) |
BR (1) | BR9711734A (en) |
CA (1) | CA2265661A1 (en) |
CO (1) | CO5031291A1 (en) |
CZ (1) | CZ83299A3 (en) |
GB (1) | GB9619074D0 (en) |
HU (1) | HUP9904401A3 (en) |
ID (1) | ID19589A (en) |
IL (1) | IL128781A0 (en) |
MA (1) | MA24359A1 (en) |
NO (1) | NO991194D0 (en) |
NZ (1) | NZ334268A (en) |
PE (1) | PE2499A1 (en) |
PL (1) | PL332074A1 (en) |
TR (1) | TR199900505T2 (en) |
WO (1) | WO1998010762A2 (en) |
ZA (1) | ZA978133B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2775597B1 (en) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE |
IL138192A0 (en) * | 1998-03-11 | 2001-11-25 | Smithkline Beecham Plc | Controlled release oral dosage forms |
DE19918325A1 (en) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
FR2796840B1 (en) | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | LOW-DOSE TABLETS AND METHOD OF PREPARATION |
US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
AR040682A1 (en) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
JP4808612B2 (en) * | 2003-04-25 | 2011-11-02 | 田辺三菱製薬株式会社 | Composition for oral administration containing alkylenedioxybenzene derivative |
EP1628642B2 (en) * | 2003-05-14 | 2013-01-23 | Aptalis Pharma Limited | Controlled drug release composition resistant to in vivo mechanic stress |
US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
JP2005272347A (en) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | Method for producing solid preparation |
JP4785847B2 (en) | 2004-08-13 | 2011-10-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof |
BRPI0513848A (en) * | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | Pramipexole prolonged-release pellet formulation or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof |
EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0392803A1 (en) * | 1989-04-13 | 1990-10-17 | Beecham Group p.l.c. | Novel compounds |
WO1995031457A1 (en) * | 1994-05-14 | 1995-11-23 | Smithkline Beecham Plc | Derivatives of quinuclidine n-oxide as muscarinic receptor ligands |
WO1996012486A1 (en) * | 1994-10-25 | 1996-05-02 | Smithkline Beecham P.L.C. | Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease |
WO1997004750A2 (en) * | 1995-07-29 | 1997-02-13 | Smithkline Beecham Plc | Process for preparing solid dosage forms of very low-dose drugs |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/en unknown
- 1997-09-08 CN CN97199411A patent/CN1235544A/en active Pending
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/en unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/en active Pending
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/en not_active Application Discontinuation
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 NZ NZ334268A patent/NZ334268A/en unknown
- 1997-09-08 IL IL12878197A patent/IL128781A0/en unknown
- 1997-09-08 BR BR9711734A patent/BR9711734A/en unknown
- 1997-09-08 PL PL97332074A patent/PL332074A1/en unknown
- 1997-09-09 CO CO97052280A patent/CO5031291A1/en unknown
- 1997-09-10 ZA ZA978133A patent/ZA978133B/en unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/en not_active Application Discontinuation
- 1997-09-10 MA MA24792A patent/MA24359A1/en unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/en not_active Application Discontinuation
- 1997-09-10 ID IDP973137A patent/ID19589A/en unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194D0/en unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0392803A1 (en) * | 1989-04-13 | 1990-10-17 | Beecham Group p.l.c. | Novel compounds |
WO1995031457A1 (en) * | 1994-05-14 | 1995-11-23 | Smithkline Beecham Plc | Derivatives of quinuclidine n-oxide as muscarinic receptor ligands |
WO1996012486A1 (en) * | 1994-10-25 | 1996-05-02 | Smithkline Beecham P.L.C. | Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease |
WO1997004750A2 (en) * | 1995-07-29 | 1997-02-13 | Smithkline Beecham Plc | Process for preparing solid dosage forms of very low-dose drugs |
Also Published As
Publication number | Publication date |
---|---|
CN1235544A (en) | 1999-11-17 |
AR008176A1 (en) | 1999-12-09 |
WO1998010762A2 (en) | 1998-03-19 |
CN1446535A (en) | 2003-10-08 |
NZ334268A (en) | 2000-10-27 |
NO991194L (en) | 1999-03-11 |
AU724086B2 (en) | 2000-09-14 |
BR9711734A (en) | 1999-08-24 |
NO991194D0 (en) | 1999-03-11 |
MA24359A1 (en) | 1998-07-01 |
CA2265661A1 (en) | 1998-03-19 |
PL332074A1 (en) | 1999-08-30 |
AU4128897A (en) | 1998-04-02 |
ID19589A (en) | 1998-07-23 |
CO5031291A1 (en) | 2001-04-27 |
EP0929301A2 (en) | 1999-07-21 |
GB9619074D0 (en) | 1996-10-23 |
TR199900505T2 (en) | 1999-06-21 |
KR20000036039A (en) | 2000-06-26 |
HUP9904401A3 (en) | 2001-03-28 |
HUP9904401A2 (en) | 2000-06-28 |
IL128781A0 (en) | 2000-01-31 |
CZ83299A3 (en) | 1999-08-11 |
PE2499A1 (en) | 1999-03-24 |
JP2001500150A (en) | 2001-01-09 |
ZA978133B (en) | 1999-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4217499A (en) | Composition having therapeutic and/or nutritionally active substituent | |
AU4651693A (en) | Methods and devices for relaxing smooth muscle contractions | |
NO308854B1 (en) | Therapeutic Compounds, Pharmaceutically Acceptable Salts and Formulations Containing the Compounds, and Uses thereof | |
AU6396598A (en) | Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders | |
AU7545594A (en) | Implantable device for the treatment of aedemas | |
EP1870103A3 (en) | Use of uridine in combination with choline for the treatment of memory disorders | |
ZA9880B (en) | Table for the controlled release of active agents | |
EP1067130A4 (en) | Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient | |
WO1998010762A3 (en) | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride | |
AU5852794A (en) | Sterilization devices, sporidical compositions, sterilization methods, and devices for reducing surface tension | |
AU3780393A (en) | Quinobenzoxazine, quinobenzothiazine, and pyrido-acridine antineoplastic agents | |
AU6410494A (en) | Device for the transdermal administration of alprazolam | |
EP0960885A4 (en) | Depsipeptides and drugs containing the same as the active ingredient | |
AU3745895A (en) | Use of gaba antagonists in the treatment of emesis | |
HUT69064A (en) | Colloidal dispersible active ingredient compositions | |
EP0681787A3 (en) | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis. | |
EP0938898A3 (en) | Treatment of pruritus | |
AU4994996A (en) | Composition for the treatment of diarrhea, its use and its preparation | |
ZA942959B (en) | Controlled release formulation. | |
AU4585993A (en) | Use of angiotensin ii antagonists for the treatment of hyperlipidaeme | |
AU4513893A (en) | Sulfamoyltriazole derivative and bactericide containing the same as active ingredient | |
AU3070192A (en) | Uses of 1,1,1,3,3,3-hexafluoropropane | |
AU6581294A (en) | Ethanolamine derivatives useful for the treatment of gastrointestinal disorders | |
ZA977957B (en) | Pharmacologically active compounds and use. | |
AU4136897A (en) | 2,3-dihydrobenzofuran derivative and hepatopathy remedy comprising the same as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97199411.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 334268 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997939064 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999/00505 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-832 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2265661 Country of ref document: CA Ref document number: 2265661 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002404 Country of ref document: MX Ref document number: 1019997002030 Country of ref document: KR Ref document number: 09254621 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 513352 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997939064 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-832 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997002030 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997939064 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997002030 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1999-832 Country of ref document: CZ |